Centessa Pharmaceuticals plc
CNTA
$29.07
$0.561.96%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.64% | -3.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.58% | 19.39% | |||
| Operating Income | 1.58% | -77.58% | |||
| Income Before Tax | -10.41% | -100.36% | |||
| Income Tax Expenses | -78.66% | -44.31% | |||
| Earnings from Continuing Operations | -9.03% | -92.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.03% | -92.63% | |||
| EBIT | 1.58% | -77.58% | |||
| EBITDA | 1.61% | -78.10% | |||
| EPS Basic | -8.63% | -91.65% | |||
| Normalized Basic EPS | -10.01% | -99.40% | |||
| EPS Diluted | -8.63% | -91.65% | |||
| Normalized Diluted EPS | -10.01% | -99.40% | |||
| Average Basic Shares Outstanding | 0.36% | 0.48% | |||
| Average Diluted Shares Outstanding | 0.36% | 0.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||